Pcv2 immunogenic compositions and methods of producing such compositions
AssigneeBoehringer Ingelheim Vetmedica GmbH
InventorsMarc Allan Eichmeyer, Gregory Paul Nitzel, Merrill Lynn Schaeffer
Life of this patent
Estimating the term…
Loading patent…
AssigneeBoehringer Ingelheim Vetmedica GmbH
InventorsMarc Allan Eichmeyer, Gregory Paul Nitzel, Merrill Lynn Schaeffer
Estimating the term…
An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time consuming extraction procedures required to separate and recover the recombinant protein from within the cells.
A kit comprising a container, wherein said container comprises:
A kit comprising a container, wherein said container comprises:
A method for aiding in the prevention or reduction of one or more of clinical symptoms associated with PCV2 infection, wherein the clinical symptoms are selected from the group consisting of PCV2 virus shedding, lymphoid infection caused by PCV2, increased mortality rate, decreased average daily weight gain, PCV2 viremia, and any combination thereof in pigs, said method comprising administering a single dose of a recombinantly produced PCV2 ORF2 antigen to a pig.
A method for the vaccination of piglets against PCV2 infection comprising the step of administering a single dose of an immunogenic composition comprising a PCV2 ORF2 antigen and a pharmaceutical-acceptable carrier to a piglet less than 15 weeks of age, wherein the piglet has anti-PCV2 antibodies, and wherein the single dose induces an immune response against PCV2 in the piglet.
Dependencies are inferred from the claim text.